4/A: AN2 Therapeutics Executive Sanjay Chanda Amends Filing to Clarify Stock Vesting Schedule
SEC Filing (Form 4/A)
Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, amends a previous SEC Form 4 filing to clarify the vesting schedule of restricted stock units.
Summary
- Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, filed an amended Form 4 with the SEC.
- The amendment clarifies details regarding the vesting schedule of restricted stock units previously reported on March 18, 2024.
- The vesting schedule specifies that 1/4th of the shares vest annually over four years from January 1, 2024, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Stakeholder Impact
- Shareholders may be interested in the details of executive compensation and equity ownership.
- The filing provides transparency regarding the terms of executive stock grants.
Key Dates
| Date | Description |
|---|---|
| 01/01/2024 | Start date for the vesting schedule of the restricted stock units. |
| 03/15/2024 | Date of the earliest transaction. |
| 03/18/2024 | Date of original Form 4 filing. |
| 03/29/2024 | Date of the amended filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.